1. | cyberspacer | |
2. | captureME | |
3. | snezhinka4 | |
4. | craymonk | |
5. | robindo |
1. | cyberspacer | |
2. | captureME | |
3. | snezhinka4 | |
4. | craymonk | |
5. | robindo |
1. | craymonk 01/31/2018 Started a nice position today. |
2. | robindo 03/26/2018 Canaccord Genuity resumes coverage as a buy, $210PT |
3. | redoctober30 06/13/2018 Share prices popped on the promising news for the pharmaceutical company. |
4. | cyberspacer 01/31/2018 BIG news out!!! - Announces SAGE-217 meets primary endpoint; co expects to initiate clinical development of SAGE-217 in disord… |
5. | cyberspacer 12/08/2017 MC is $6.4 bil |
6. | cyberspacer 02/07/2018 Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder |
7. | captureME 02/07/2018 Commences $575 mln common stock offering |
8. | snezhinka4 04/10/2018 Deal rumors swirling following headlines that the company has cancelled out of an upcoming conference presen… |
9. | craymonk 12/08/2017 Wow, out of the loop |
10. | captureME 12/07/2017 This Biotech Catapults 70% Higher On Depression Drug Results |